Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

In ‘Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD,’ our panel delves into the challenges and strategies surrounding patient communication in cardiovascular risk management, emphasizing that clinical decision-making must be guided by overall risk profile rather than individual lipid or blood pressure values in isolation. The discussion opens with the observation that most patients do not present with dramatically elevated cholesterol or blood pressure, yet remain at significant cardiovascular risk, making it essential for clinicians to communicate risk in meaningful, accessible terms. The panelists highlight high-risk conditions such as type 2 diabetes, noting that a patient with longstanding diabetes and end-organ damage carries a very high cardiovascular risk regardless of whether their LDL appears only modestly elevated. Rather than framing elevated LDL as a problem, the panel advocates for reframing lipid-lowering therapy through a prevention lens, with one panelist describing the approach of presenting statin therapy as a "vitamin" capable of reducing heart attack and stroke risk by 30 to 50% over a lifetime. For high-risk diabetic patients, the LDL goal of less than 70 mg/dL is positioned not as a correction of abnormality but as an opportunity to prevent cardiovascular disease, the leading cause of death in this population.

The conversation broadens to address other cardiovascular disease drivers beyond atherosclerosis, including hypertension-related heart failure, stroke, and kidney disease, reinforcing that global risk assessment must account for multiple converging factors rather than relying on single threshold values to trigger treatment.

Our next episode, 'Navigating Combination Therapy and Access Challenges in ASCVD,' further explores ASCVD, highlighting the complexities of initiating and escalating lipid-lowering therapy in asymptomatic patients, and examining how clinicians navigate treatment decisions amid patient concerns, formulary constraints, and access barriers to advanced therapies.